ELAN Stock Cash Flow Statements

Elanco Animal Health Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Elanco Animal Health Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31

cash flows from operating activities
net income	11,000,000	67,000,000	-8,000,000	364,000,000	-50,000,000	32,000,000	-141,000,000	-1,096,000,000	-97,000,000	103,000,000	-55,000,000	-49,000,000	-22,000,000	48,000,000	-97,000,000	-104,000,000	-210,000,000	-61,000,000	-322,800,000	-135,000,000	-53,200,000	-49,100,000	-9,500,000	10,000,000	35,900,000	31,500,000
adjustments to reconcile net income to cash flows from operating activities:
depreciation and amortization	169,000,000	161,000,000	164,000,000	170,000,000	162,000,000	166,000,000	171,000,000	173,000,000	177,000,000	173,000,000	168,000,000	167,000,000	171,000,000	176,000,000	174,000,000	170,000,000	170,000,000	202,000,000	222,200,000	132,300,000	80,900,000	81,500,000	83,400,000	78,700,000	69,300,000	83,100,000
stock-based compensation expense	20,000,000	15,000,000	15,000,000	15,000,000	14,000,000	11,000,000	15,000,000	10,000,000	9,000,000	12,000,000	15,000,000	13,000,000	17,000,000	14,000,000	18,000,000	17,000,000	16,000,000	15,000,000	16,600,000	11,700,000	8,300,000	11,100,000	12,700,000	14,800,000	14,200,000	7,700,000
asset impairment and write-down charges			5,000,000	15,000,000			27,000,000				-6,000,000	0	59,000,000	28,000,000	5,000,000	56,000,000
sold portion of royalty revenue
interest on liability for sale of future revenue
changes in operating assets and liabilities, net of acquisitions and divestitures	52,000,000	-237,000,000		248,000,000	22,000,000	-177,000,000
other non-cash operating activities	-18,000,000	-10,000,000	57,000,000	-15,000,000	-9,000,000	-30,000,000	17,000,000	-20,000,000	10,000,000	2,000,000	-13,000,000	-10,000,000	8,000,000	13,000,000	-1,000,000			10,000,000	-28,900,000	44,000,000	5,100,000	-500,000	7,300,000	2,600,000	-13,200,000	-9,400,000
net cash from operating activities	237,000,000	-4,000,000	177,000,000	162,000,000	200,000,000	2,000,000	157,000,000	198,000,000	61,000,000	-145,000,000	13,000,000	189,000,000	312,000,000	-62,000,000	223,000,000	89,000,000	149,000,000	22,000,000	-92,900,000	-111,700,000	159,300,000	4,300,000	126,300,000	39,600,000	52,600,000	5,600,000
capex	-57,000,000	-65,000,000	-47,000,000	-42,000,000	-34,000,000	-24,000,000	0	-33,000,000	0	-20,000,000	0	-26,000,000	-26,000,000	-19,000,000	0	0	0	-18,000,000	0	0	0	-12,600,000	0	-34,200,000	-23,800,000	-28,000,000
free cash flows	180,000,000	-69,000,000	130,000,000	120,000,000	166,000,000	-22,000,000	157,000,000	165,000,000	61,000,000	-165,000,000	13,000,000	163,000,000	286,000,000	-81,000,000	223,000,000	89,000,000	149,000,000	4,000,000	-92,900,000	-111,700,000	159,300,000	-8,300,000	126,300,000	5,400,000	28,800,000	-22,400,000
cash flows from investing activities
net purchases of property and equipment and software	-57,000,000	-65,000,000	-47,000,000	-42,000,000	-34,000,000	-24,000,000		-33,000,000
proceeds from divestitures	0	9,000,000
other investing activities	1,000,000	-2,000,000		0			6,000,000	0	-1,000,000	-1,000,000	1,000,000	-2,000,000	-4,000,000	-3,000,000	0	-1,000,000	0	-7,000,000	900,000	-6,700,000	-900,000	-400,000	36,800,000	-16,000,000	-25,200,000	-500,000
net cash from investing activities	-56,000,000	-58,000,000	-90,000,000	1,244,000,000	-33,000,000	37,000,000	-35,000,000	-36,000,000	-43,000,000	-55,000,000	-76,000,000	-37,000,000	-37,000,000	-29,000,000	-74,000,000	-441,000,000	-25,000,000	10,000,000	-73,300,000	-4,696,900,000	10,600,000	-19,600,000	-74,300,000	-83,000,000	-49,000,000	-28,500,000
cash flows from financing activities
proceeds from revolving credit facility	0	125,000,000	0	0	0	50,000,000	0	100,000,000	50,000,000	200,000,000	0	0	500,000,000	63,000,000
repayments of revolving credit facility	0	-125,000,000	0	0	-200,000,000	-50,000,000	-97,000,000				0	-75,000,000	-575,000,000	-163,000,000
proceeds from securitization facility	0	125,000,000	0	0	120,000,000	50,000,000	0
repayments of securitization facility	-85,000,000	-40,000,000	-25,000,000	-120,000,000	0	-50,000,000	-28,000,000
repayments of long-term borrowings	-361,000,000	-13,000,000	-13,000,000	-1,562,000,000	-12,000,000	-13,000,000	-14,000,000	-356,000,000	-13,000,000	-19,000,000	-70,000,000	-79,000,000	-439,000,000	-89,000,000
proceeds from sale of future revenue, net of transaction costs
other financing activities	0	-20,000,000	6,000,000	-8,000,000	-1,000,000	-14,000,000	0	-1,000,000	2,000,000	-7,000,000	1,000,000	0	-6,000,000	-11,000,000	-12,000,000	0	0	-17,000,000	-1,000,000	-1,000,000	-1,400,000	-12,800,000	-100,000	300,000	1,900,000	-500,000
net cash from financing activities	-156,000,000	52,000,000	-32,000,000	-1,340,000,000	-93,000,000	-27,000,000	-139,000,000	-157,000,000	39,000,000	174,000,000	-84,000,000	-169,000,000	-96,000,000	-200,000,000	44,000,000	231,000,000	-67,000,000	2,000,000	-18,300,000	4,068,300,000	7,300,000	896,600,000	-6,200,000	-48,800,000	89,700,000	-339,500,000
effect of exchange rate changes on cash and cash equivalents	27,000,000	29,000,000	-77,000,000	8,000,000	-3,000,000	-19,000,000	0	-3,000,000	-8,000,000	-1,000,000	32,000,000	-30,000,000	-14,000,000	-5,000,000	-8,000,000	-6,000,000	8,000,000	-25,000,000	19,300,000	9,100,000	7,500,000	-9,300,000	-21,000,000	15,900,000	2,700,000	-14,500,000
net increase in cash and cash equivalents	52,000,000	19,000,000	-22,000,000	74,000,000			-17,000,000	2,000,000					165,000,000	-296,000,000
cash and cash equivalents – beginning of period	0	468,000,000		0	0	352,000,000		0
cash and cash equivalents – end of period	52,000,000	487,000,000		74,000,000	71,000,000	345,000,000		2,000,000
supplemental disclosure of non-cash investing and financing activities:
right-of-use assets obtained in exchange for new finance lease liability
goodwill impairment							0
deferred income taxes										2,000,000	-21,000,000	4,000,000	-29,000,000	-11,000,000
gain on divestiture			0									0
loss on extinguishment of debt											1,000,000	2,000,000
proceeds from interest rate swap settlements			0				0				0	75,000,000
other changes in operating assets and liabilities, net of acquisitions and divestitures:
receivables
inventories
other assets
accounts payable and other liabilities
purchases of intangible assets			-6,000,000				0	0	0	-14,000,000	-2,000,000	-10,000,000			-3,000,000	-1,000,000	-1,000,000	-33,000,000
cash paid for acquisitions			-36,000,000	0	0	-5,000,000		-3,000,000	0	-16,000,000
proceeds from aqua business divestiture
proceeds from sale of shawnee and speke facilities					0	66,000,000
proceeds from issuance of long-term debt			0								0	0			0				250,000,000	4,475,000,000	0	79,200,000
funding related to construction of corporate headquarters
cash and cash equivalents at january 1										345,000,000		0	0	638,000,000
cash and cash equivalents at december 31
proceeds from business divestitures
proceeds from previous sale of shawnee and speke facilities
net decrease in cash and cash equivalents						-7,000,000				-27,000,000
inventory fair value step-up amortization										1,000,000					0	1,000,000	1,000,000	62,000,000
other changes in operating assets and liabilities																										-127,600,000
purchases of property and equipment and software
cash paid for acquisitions, net of cash acquired															0	-415,000,000	0	73,000,000	0				0
changes in operating assets and liabilities, net of acquisitions								27,000,000	-34,000,000	-439,000,000						-53,000,000	-7,000,000	-183,000,000
loss on sale of assets										1,000,000		2,000,000
net purchases of property and equipment										-20,000,000		-26,000,000	-26,000,000	-19,000,000				-18,000,000				-12,600,000		-34,200,000	-23,800,000	-28,000,000
purchases of software										-4,000,000	-11,000,000	-10,000,000	-6,000,000	-7,000,000	-22,000,000	1,000,000	-7,000,000	-5,000,000	-28,500,000	-88,200,000	-27,800,000	-31,800,000
cash and cash equivalents at march 31										318,000,000				342,000,000
gain on sale of assets														1,000,000					0	0	-47,500,000	-3,800,000
gain on divestitures															-1,000,000				-300,000
purchases of property and equipment
disposals of property and equipment
divestiture proceeds																			0
proceeds from issuance of common stock and tangible equity units																			0	0	0	1,219,900,000
debt issuance costs											0	-1,000,000			-1,000,000				0	-99,300,000	-100,000	-3,100,000
early redemption and tender premiums paid											0
net increase in cash, cash equivalents and restricted cash															185,000,000	-127,000,000	65,000,000	9,000,000	-165,200,000	-731,200,000	184,700,000	872,000,000	24,800,000
cash, cash equivalents and restricted cash at january 1															0	0	0	506,000,000	0	0	0	345,100,000	0	0	0	677,500,000
cash, cash equivalents and restricted cash at december 31
proceeds from site divestitures
other net financing transactions with lilly																0	0	-11,000,000				-15,200,000		1,300,000	161,400,000	-156,400,000
cash and cash equivalents at september 30
changes in operating assets and liabilities													-38,000,000	-331,000,000							215,500,000	-9,800,000		-61,800,000
cash and cash equivalents at june 30
deferred income tax benefit
consideration paid to lilly in connection with the separation																							0	-400,000	-16,100,000	-175,100,000
change in deferred income taxes																-5,000,000	-82,000,000	-32,000,000	35,000,000	-81,400,000	-53,300,000	-25,100,000	-14,800,000	-25,400,000	24,000,000	16,300,000
proceeds from settlement of net investment hedges																			0	0	7,500,000	25,200,000
proceeds from product divestitures
repayments of borrowings																-518,000,000	-17,000,000	-20,000,000		-306,400,000	-6,400,000	-371,400,000	-6,100,000	-50,000,000	-57,500,000	-7,500,000
net proceeds from revolving credit facility																		50,000,000
cash, cash equivalents and restricted cash at september 30
net proceeds from sale (purchases) of property and equipment																				-35,400,000
cash, cash equivalents and restricted cash at june 30
asset impairment charges																		9,000,000	20,400,000	1,200,000			7,900,000	20,700,000	0	4,000,000
cash, cash equivalents and restricted cash at march 31																		515,000,000				1,217,100,000				300,600,000
other net transactions with lilly
proceeds from issuance of common stock
cash, cash equivalents and restricted cash at september 30, 2019
net decrease in cash, cash equivalents and restricted cash																									96,000,000	-376,900,000
other changes in operating assets and liabilities, net of acquisitions and divestitures

We provide you with 20 years of cash flow statements for Elanco Animal Health stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Elanco Animal Health stock. Explore the full financial landscape of Elanco Animal Health stock with our expertly curated income statements.

The information provided in this report about Elanco Animal Health stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.